Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 2208-2210

  Zorrilla, Carmen D ^a   Van Dyke, Russell ^b   Bardeguez, Arlene ^c   Acosta, Edward P ^d   Smith, Betsy ^e   Hughes, Michael D ^f   Huang, Sharon ^f   Watts, D Heather ^g   Heckman, Barbara ^h   Jiménez, Eleanor ⁱ   McSherry, George ^c   Mofenson, Lynne ^h  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁱ San Juan City Hospital   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMYLASE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ANEMIA; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INFANT; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SAQUINAVIR; TREATMENT OUTCOME;

EID: 34250171196     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00871-06     Document Type: Article

References (9)

1. Acosta, E. P., A. Bardeguez, C. D. Zorrilla, R. Van Dyke, M. D. Hughes, S. Huang, L. Pompeo, A. M. Stek, J. Pitt, D. H. Watts, E. Smith, E. Jimenez, L. Mofenson, and the Pediatric AIDS Clinical Trials Group 386 Protocol Team. 2004. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 48:430-436.
2. Acosta, E. P., C. Zorrilla, R. Van Dyke, A. Bardeguez, E. Smith, M. Hughes, S. Huang, J. Pitt, H. Watts, L. Mofenson, and the Pediatric AIDS Clinical Trials Group 386 Protocol Team. 2001. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin. Trials 2:460-465.
3. AIDS Clinical Trials Group. Accessed 28 November 2006. Toxicity tables. http://rcc.tech-res-intl.com./tox_tables.htm.
4. + subjects, abstr. 126. Program Abstr. 9th Conf. Retrovir. Opportun. Infect., Seattle, WA, 24 to 28 February 2002.
5. Bryson, V., A. Stek, M. Mirochnick, L. Mofenson, J. Connor, H. Watts, S. Huang, M. Hughes, B. Cunningham, L. Purdue, Y. Asfaw, and E. Smith for the PACTG 353 Team. 2002. Pharmacokinetics, antiviral activity and safety of nelfinavir (NFV) in combination with ZDV/3TC in pregnant HIV-infected women and their infants: PACTG 353 cohort 2, abstr. 795-W. Program Abstr. 9th Conf. Retrovir. Opportun. Infect., Seattle, WA, 24 to 28 February 2002.
6. Cortes-Lopez, L. F., R. Ruiz-Valderas, R. Pascual, M. Rodriguez, and A. Marin Niebla. 2003. Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100mg) in HIV-infected pregnant women: pharmacokinetics and efficacy. HIV Clin. Trials 4:227-229.
7. Hanlon, M., S. O'Dea, S. Woods, H. McDermont, H. Rajab, S. Coughlam, S. Clarke, and F. Mulcahy. 2006. Evaluation of ritonavir/saquinavir-based regimens in the prevention of mother-to-child transmission of HIV, abstr. 721. Program Abstr. 13th Conf. Retrovir. Opportun. Infect., Denver, CO, 5 to 8 February 2006.
8. Public Health Service Task Force. 2006. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.
9. Stek, A., M. Mirochnick, E. Capparelli, B. Best, S. K. Burchett, C. Hu, J. Gardella, C. Elgie, J. Schiffhauer, E. Smith, J. Read, and R. Tuomala. 2004. Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026, abstr. LBOrB08. Program Abstr. XV Int. AIDS Conf., Bangkok, Thailand, 11 to 16 July 2004.